Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
Neil J KormanRichard Bruce WarrenJerry BagelApril W ArmstrongMelinda J GooderhamBruce E StroberDiamant ThaҫiAkimichi MoritaShinichi ImafukuPeter FoleyHoward SofenMin ZhengLauren HippeliRenata M KisaSubhashis BanerjeeAndrew BlauveltPublished in: The Journal of dermatological treatment (2024)
Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.